Availability of Ozempic®

HPS Pharmacies wish to advise that Novo Nordisk is continuing to experience a supply interruption for Ozempic^® as follows:

Ozempic^® 0.25/0.5mg Pen
Semaglutide 1.34mg/mL
ARTG 308324

Ozempic^® 1mg Pen
Semaglutide 1.34mg/mL
ARTG 315107

Novo Nordisk has advised the Therapeutic Goods Administration (TGA) that Ozempic^® supplies will remain limited for the rest of 2024. Internationally registered alternatives have been approved for supply under Section 19A of the Therapeutic Goods Act 1989. These alternative products are currently not subsidised on the Pharmaceutical Benefits Scheme (PBS).

As it is not known when sufficient quantities of Ozempic^® will be available to meet demand, the TGA provides the following advice for prescribers:

• Do not initiate new patients on semaglutide unless there are no suitable alternatives or there is a compelling clinical reason to do so;
• Consider if patients already prescribed semaglutide could be changed to an alternative; and
• Conserve supplies for patients who are stabilised on semaglutide who have no other treatment options.

For more information, please go to the Ozempic (semaglutide) shortage page available on the TGA website.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.

Download PDF